Remzi Bag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Remzi Bag has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
Charles G. Alex
4 shared publicationsHarish Seethamraju
4 shared publicationsMaher A. Baz
4 shared publicationsMaher Baz
Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA, mayo.edu
4 shared publicationsRobert B. Love
4 shared publicationsSelim M. Arcasoy
4 shared publications
Latest Publications
- 1 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e272182
Beware the tick: ehrlichiosis in a lung transplant recipient
Ehrlichiosis is a rare tick-borne zoonosis caused by Ehrlichia chaffeensis , E. ewingii and related species. In solid organ transplant recipients, immunosuppression can result in atypical presentations, delayed diagnosis and poor outcomes. The disease remains under-recognised among lung transplant recipients despite its potentially fatal course. A man in his early 70s with a history of bilateral lung transplantation for chronic obstructive pulmonary disease presented with a high-grade fever and shortness of breath. Bronchoalveolar lavage (BAL) culture grew Pseudomonas aeruginosa and meropenem was initiated. He subsequently developed severe thrombocytopenia, acute kidney injury and elevated liver transaminases. Disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic purpura (TTP) were excluded, while haemophagocytic lymphohistiocytosis (HLH) was considered but not confirmed. His condition rapidly progressed to multiorgan failure requiring mechanical ventilation and haemodialysis. E. chaffeensis was identified postmortem by next-generation sequencing. This case highlights diagnostic challenges and the importance of early empiric doxycycline therapy in endemic areas.
- 1 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e272182
Beware the tick: ehrlichiosis in a lung transplant recipient
Ehrlichiosis is a rare tick-borne zoonosis caused by Ehrlichia chaffeensis , E. ewingii and related species. In solid organ transplant recipients, immunosuppression can result in atypical presentations, delayed diagnosis and poor outcomes. The disease remains under-recognised among lung transplant recipients despite its potentially fatal course. A man in his early 70s with a history of bilateral lung transplantation for chronic obstructive pulmonary disease presented with a high-grade fever and shortness of breath. Bronchoalveolar lavage (BAL) culture grew Pseudomonas aeruginosa and meropenem was initiated. He subsequently developed severe thrombocytopenia, acute kidney injury and elevated liver transaminases. Disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic purpura (TTP) were excluded, while haemophagocytic lymphohistiocytosis (HLH) was considered but not confirmed. His condition rapidly progressed to multiorgan failure requiring mechanical ventilation and haemodialysis. E. chaffeensis was identified postmortem by next-generation sequencing. This case highlights diagnostic challenges and the importance of early empiric doxycycline therapy in endemic areas.
- Open Access
- 26 June 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70657
Usual Interstitial Pneumonia in a Patient With Celiac Disease: Expanding the Spectrum of Pulmonary Manifestations
Celiac disease (CD) is an autoimmune enteropathy with recognized extraintestinal manifestations. We describe a 55‐year‐old man with long‐standing, well‐controlled CD who developed progressive shortness of breath and cough. Imaging was indeterminate for usual interstitial pneumonia (UIP), and a surgical lung biopsy demonstrated a UIP pattern. Autoimmune serologies were negative, and no alternate etiologies for UIP were identified. With intermittent adherence to a gluten‐free diet and medical management including nintedanib, his disease progressed, ultimately leading to lung transplantation. This case raises the possibility of an association between CD and UIP of uncertain aetiology and should prompt further discussion as the relationship remains unclear. To contextualize this observation, we conducted a systematic review of published case reports evaluating pulmonary manifestations of celiac disease.
- 26 June 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70657
Open AccessUsual Interstitial Pneumonia in a Patient With Celiac Disease: Expanding the Spectrum of Pulmonary Manifestations
Celiac disease (CD) is an autoimmune enteropathy with recognized extraintestinal manifestations. We describe a 55‐year‐old man with long‐standing, well‐controlled CD who developed progressive shortness of breath and cough. Imaging was indeterminate for usual interstitial pneumonia (UIP), and a surgical lung biopsy demonstrated a UIP pattern. Autoimmune serologies were negative, and no alternate etiologies for UIP were identified. With intermittent adherence to a gluten‐free diet and medical management including nintedanib, his disease progressed, ultimately leading to lung transplantation. This case raises the possibility of an association between CD and UIP of uncertain aetiology and should prompt further discussion as the relationship remains unclear. To contextualize this observation, we conducted a systematic review of published case reports evaluating pulmonary manifestations of celiac disease.
- 27 April 2026
- Published by Springer Nature in Lung
- Vol. 204 (1)
Metagenomic Microbial Next-Generation Gene Sequencing as a Noninvasive Diagnostic Tool in Adult Lung Transplantation: A Retrospective Case Series
- 27 April 2026
- Published by Springer Nature in Lung
- Vol. 204 (1)
Metagenomic Microbial Next-Generation Gene Sequencing as a Noninvasive Diagnostic Tool in Adult Lung Transplantation: A Retrospective Case Series
- Open Access
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e3558336
Feasibility and Safety of 1.1‐mm Cryobiopsy for Acute Rejection Surveillance in Lung Transplant Recipients: A Comparative Study and Review of the Literature
Background: Identifying graft rejection after lung transplantation remains challenging, and no consensus exists on the optimal surveillance strategy. Transbronchial forceps biopsy (FBx) is the conventional method but is limited by small sample size and crush artifacts. Sheath‐guided cryobiopsy (CBx) using a novel 1.1‐mm probe has emerged as a promising alternative. This study evaluates the feasibility and safety of the 1.1‐mm cryoprobe and provides a focused review of current literature. Methods: We conducted a retrospective observational single‐center study between October 2022 and January 2023 of adult lung transplant recipients who underwent transbronchial biopsies for surveillance. Procedures were performed using either standard FBx or the 1.1‐mm cryoprobe. Descriptive analyses compared feasibility and safety between groups. Results: We identified 72 lung transplant recipients who underwent 109 surveillance biopsies. A total of n = 56 CBx and n = 53 FBx procedures were performed. The median procedure time was 20 min (IQR 17–26) in the CBx group versus 22 min (IQR 15–33) in the FBx group. We found a statistically higher median sample area for CBx compared with FBx (11 vs. 6 mm 2 , p < 0.01). No pneumothorax or postprocedural respiratory failure occurred in either group. Conclusion: CBx with a 1.1‐mm probe provides larger histological samples than FBx, with comparable safety and potentially shorter procedural times. These findings support its feasibility for lung transplant surveillance.
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e3558336
Open AccessFeasibility and Safety of 1.1‐mm Cryobiopsy for Acute Rejection Surveillance in Lung Transplant Recipients: A Comparative Study and Review of the Literature
Background: Identifying graft rejection after lung transplantation remains challenging, and no consensus exists on the optimal surveillance strategy. Transbronchial forceps biopsy (FBx) is the conventional method but is limited by small sample size and crush artifacts. Sheath‐guided cryobiopsy (CBx) using a novel 1.1‐mm probe has emerged as a promising alternative. This study evaluates the feasibility and safety of the 1.1‐mm cryoprobe and provides a focused review of current literature. Methods: We conducted a retrospective observational single‐center study between October 2022 and January 2023 of adult lung transplant recipients who underwent transbronchial biopsies for surveillance. Procedures were performed using either standard FBx or the 1.1‐mm cryoprobe. Descriptive analyses compared feasibility and safety between groups. Results: We identified 72 lung transplant recipients who underwent 109 surveillance biopsies. A total of n = 56 CBx and n = 53 FBx procedures were performed. The median procedure time was 20 min (IQR 17–26) in the CBx group versus 22 min (IQR 15–33) in the FBx group. We found a statistically higher median sample area for CBx compared with FBx (11 vs. 6 mm 2 , p < 0.01). No pneumothorax or postprocedural respiratory failure occurred in either group. Conclusion: CBx with a 1.1‐mm probe provides larger histological samples than FBx, with comparable safety and potentially shorter procedural times. These findings support its feasibility for lung transplant surveillance.
- 30 December 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (12) , e269632
Absence of interlobular septal thickening in complete pulmonary vein obstruction
- 30 December 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (12) , e269632
Absence of interlobular septal thickening in complete pulmonary vein obstruction
- 29 March 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 241, 108061
Comparing the 1.1 mm cryoprobe versus flexible forceps for lung transplant acute allograft rejection diagnosis
- 29 March 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 241, 108061
Comparing the 1.1 mm cryoprobe versus flexible forceps for lung transplant acute allograft rejection diagnosis
- Open Access
- 1 March 2025
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 17 (3) , 153-163
Oral Pulmonary Arterial Hypertension-Targeted Therapy in Patients With Pulmonary Hypertension due to Interstitial Lung Disease
Background: The aim of the study was to determine whether treatment with oral pulmonary arterial hypertension (PAH)-targeted therapy is associated with functional or hemodynamic improvement in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD). Methods: We conducted a retrospective review of 1,507 consented patients with pulmonary hypertension (PH) from the University of Chicago PH Registry. Exclusion criteria included: enrollment in PH-related clinical trials, use of inhaled treprostinil or iloprost and prior PAH-targeted therapy initiated before consenting to registry enrollment, thus precluding baseline data. Data analyzed included demographics, interstitial lung disease (ILD) classification, PAH-targeted therapy, functional data, hemodynamics, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) before and after initiation of treatment. Data were analyzed using paired t-test, or related-samples Wilcoxon signed rank test. Results: Of 37 patients included, 27 (73%) received treatment with one PAH-targeted therapy and nine (24%) received dual therapy. At baseline, median NT-proBNP was 1,498 ng/dL (675 - 3,208), mean pulmonary artery pressure (mPAP) was 45 ± 11 mm Hg, and pulmonary vascular resistance (PVR) of 9 ± 4 Wood units (WU). In patients with measurements both before and after treatment with PAH-targeted therapy, there was a decrease in PVR (n = 13, 8 vs. 5 WU, P < 0.001), an increase in cardiac output (n = 13, 4 vs. 5 L/min, P = 0.014), and a decrease in NT-proBNP levels (n = 26, 1,421 vs. 842 ng/dL, P = 0.045). Conclusions: In this study, use of PAH-targeted therapy in patients with PH-ILD was associated with statistically significant and clinically meaningful improvements in NT-proBNP and pulmonary hemodynamics.
- 1 March 2025
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 17 (3) , 153-163
Open AccessOral Pulmonary Arterial Hypertension-Targeted Therapy in Patients With Pulmonary Hypertension due to Interstitial Lung Disease
Background: The aim of the study was to determine whether treatment with oral pulmonary arterial hypertension (PAH)-targeted therapy is associated with functional or hemodynamic improvement in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD). Methods: We conducted a retrospective review of 1,507 consented patients with pulmonary hypertension (PH) from the University of Chicago PH Registry. Exclusion criteria included: enrollment in PH-related clinical trials, use of inhaled treprostinil or iloprost and prior PAH-targeted therapy initiated before consenting to registry enrollment, thus precluding baseline data. Data analyzed included demographics, interstitial lung disease (ILD) classification, PAH-targeted therapy, functional data, hemodynamics, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) before and after initiation of treatment. Data were analyzed using paired t-test, or related-samples Wilcoxon signed rank test. Results: Of 37 patients included, 27 (73%) received treatment with one PAH-targeted therapy and nine (24%) received dual therapy. At baseline, median NT-proBNP was 1,498 ng/dL (675 - 3,208), mean pulmonary artery pressure (mPAP) was 45 ± 11 mm Hg, and pulmonary vascular resistance (PVR) of 9 ± 4 Wood units (WU). In patients with measurements both before and after treatment with PAH-targeted therapy, there was a decrease in PVR (n = 13, 8 vs. 5 WU, P < 0.001), an increase in cardiac output (n = 13, 4 vs. 5 L/min, P = 0.014), and a decrease in NT-proBNP levels (n = 26, 1,421 vs. 842 ng/dL, P = 0.045). Conclusions: In this study, use of PAH-targeted therapy in patients with PH-ILD was associated with statistically significant and clinically meaningful improvements in NT-proBNP and pulmonary hemodynamics.
- 3 August 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (6) , 1454-1456
Chromoblastomycosis: A Potential Mimic of Squamous Cell Carcinoma in Transplant Recipients
- 3 August 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (6) , 1454-1456
Chromoblastomycosis: A Potential Mimic of Squamous Cell Carcinoma in Transplant Recipients
- Open Access
- 17 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts
Pulmonary fibrosis (PF) is characterized by profound scarring and poor survival. We investigated the association of leukocyte telomere length (LTL) with chronological age and mortality across racially diverse PF cohorts. LTL measurements among participants with PF stratified by race/ethnicity were assessed in relation to age and all-cause mortality, and compared to controls. Generalized linear models were used to evaluate the age-LTL relationship, Cox proportional hazards models were used for hazard ratio estimation, and the Cochran–Armitage test was used to assess quartiles of LTL. Standardized LTL shortened with increasing chronological age; this association in controls was strengthened in PF (R = −0.28; P < 0.0001). In PF, age- and sex-adjusted LTL below the median consistently predicted worse mortality across all racial groups (White, HR = 2.21, 95% CI = 1.79–2.72; Black, HR = 2.22, 95% CI = 1.05–4.66; Hispanic, HR = 3.40, 95% CI = 1.88–6.14; and Asian, HR = 2.11, 95% CI = 0.55–8.23). LTL associates uniformly with chronological age and is a biomarker predictive of mortality in PF across racial groups.
- 17 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Open AccessTelomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts
Pulmonary fibrosis (PF) is characterized by profound scarring and poor survival. We investigated the association of leukocyte telomere length (LTL) with chronological age and mortality across racially diverse PF cohorts. LTL measurements among participants with PF stratified by race/ethnicity were assessed in relation to age and all-cause mortality, and compared to controls. Generalized linear models were used to evaluate the age-LTL relationship, Cox proportional hazards models were used for hazard ratio estimation, and the Cochran–Armitage test was used to assess quartiles of LTL. Standardized LTL shortened with increasing chronological age; this association in controls was strengthened in PF (R = −0.28; P < 0.0001). In PF, age- and sex-adjusted LTL below the median consistently predicted worse mortality across all racial groups (White, HR = 2.21, 95% CI = 1.79–2.72; Black, HR = 2.22, 95% CI = 1.05–4.66; Hispanic, HR = 3.40, 95% CI = 1.88–6.14; and Asian, HR = 2.11, 95% CI = 0.55–8.23). LTL associates uniformly with chronological age and is a biomarker predictive of mortality in PF across racial groups.